a b s t r a c t (R)-Goniothalamin, is a member of styryl lactones, possesses selective cytotoxicity against cancer cell lines. In this work, replacement of styryl substituent with 2-naphthyl and 3-quinoyl gave new analogues which may have less conformational changes compared to the lead compound. Anti-proliferative tests indicated that 2-naphthyl substituted (R)-5,6-dihydro-2H-pyran-2-one has slightly better cytotoxicity than (R)-goniothalamin. To clarify the effect of 2-naphthyl substituent additional aryl substituted (R)-5,6-dihydro-2H-pyran-2-ones have been synthesized enantioselectively and tested against PC-3 and MCF-7 cell lines.
Introduction
One of the important issues of medicinal chemistry is to design compounds which selectively target the cancer cells preferably with no or minimized activity against normal cells. Goniothalamin (1), a naturally occurring styryl lactone, can be considered as a good lead compound for this purpose. Goniothalamin was first isolated from Cryptocarya caloneura in 1967, 1 and later from the other natural sources ( Fig. 1 ). [2] [3] [4] [5] [6] [7] Besides weak antibacterial and strong antifungal activity of 1, 8 (R)-goniothalamin (1a) has shown significant cytotoxicity against a variety of cancer cell lines like HeLa, HGC-27, MCF-7, T47D, MDA-MB-231, Caov-3, HL-60, NCI ADR, NCI 460, UACC62, 786-0, OVCAR03, PCO 3, and HT 29 in vitro. [9] [10] [11] [12] [13] [14] [15] Pihie and coworkers have shown that, 1a has no significant cytotoxicity toward non-malignant cells, 10 which implies that it has activity mainly in malignant cells. Its tumoricidal and tumoristatic effects have also been reported in vivo. 16 Recent studies showed that several (S)-goniothalamin (1b) derivatives, enantiomer of 1a, also have similar cytotoxic activity against several tumor cell lines (Fig. 2 ). 17 Although the mechanism of action of the goniothalamin derivatives is not fully understood yet, several studies demonstrated that 1a is a potential genotoxic substance. 18 Besides the caspase-9 activation and loss of mitochondrial membrane potential of the HL-60 leukemia cells, 13 it is also responsible for an increase in 0968 Bax (pro-apoptotic protein) levels, 12, 14 and for the activation of p53 tumor suppressor protein. 16 Because of the interesting biological activities of 1a and 1b, several asymmetric synthesis routes have been developed mainly in the last decade. 15, 17, [19] [20] [21] [22] [23] [24] [25] In this work, we represent the asymmetric synthesis and biological activities of three new conformationally constrained analogues of (R)-and (S)-goniothalamin (4, 5, and 11, Fig. 3 ) and five additional 6-aryl substituted (R)-5,6-dihydro-2H-pyran-2-ones.
Results and discussion
Up to date, there is limited information about the activity structure relationship (SAR) of goniothalamin analogues. Two recently published works made contributions to the literature in this manner. de Fatima et al. showed that (R)-goniothalamin analogue, having cis-double bond between the carbons in the linker part (2) , was 2-fold less cytotoxic compared to 1a towards the tested cancer cell lines except breast cell lines (MCF-7 and NCI ADR). In the same study another (R)-goniothalamin analogue, having ether functionality in the linker part (3), has been synthesized and evaluated against 8 different cancer cells. Although compound 3 shows 2-6 times lower cytotoxicity than 1a towards five of the selected cancer cells, 3 had comparatively better activity in the cell lines MCF-7, OVCAR03, and PCO. 15 It is believed that Michael acceptor and the trans-oriented double bond in the linker parts were essential for biological activity (Fig. 1 ). In this work, to better understand the role of the linker part, 2-napthyl and 3-quinoyl structures are proposed in the place of phenyl ring and trans-oriented linker part (4, 5, and 11). By this way, rotation around the single bond between the phenyl ring and linker will be restricted and it may form fully planar structure.
The enantioselective synthesis of target compounds has been accomplished by method developed by de Fatima et al. 15 As shown in Table 1 , asymmetric allylation of aldehydes (12a-g) gave (R)homoallylic alcohols (13a-g) in the presence of l-oxobis(R-binaphthoxy) (isopropoxy)titanium complex. When S-BINOL was used in the same reaction (S)-homoallylic alcohol (15) was produced. The enantiomeric excesses of the alcohols were determined by HPLC studies by employing Chiracel AD-H column (i-propanol/ hexane mixtures as eluent). Yields and enantiomeric excesses were reported in Table 1 . In the second step purified alcohols were acrylated in the presence of acryloylchloride and triethylamine to form esters 14a-g and 16. Ring closing metathesis yielded the final products 4-11. Enantiomeric excesses of all products were calcu-lated on the basis of chiral HPLC studies as reported above. Through the synthesis, enantiomeric excesses of 3-phenoxyphenyl substituted derivatives (13g, 14g, and 10) were almost same. On the other hand, when the substituent has been changed to a bicycloaryl group enantiomeric excess of the products fluctuated in all steps. The most dramatic changes in enantiomeric excesses have been observed during the synthesis of compounds 6 and 11. Although these two compounds tended to yield racemic mixtures in chromatography, enantiomeric enrichment was observed in the synthesis of compounds 5 and 7-9. Enantiomeric enrichment was first reported by Crooks et al., 26 and such enrichment processes were reported for many different compounds, 27 including molecules having benzylic hydrogen on the chiral carbon. 28 As a reference in cytotoxicity tests, racemic goniothalamin (1) was prepared according to the literature, defined by Fatima et al. in the absence of R-BINOL (59) with 36% overall yield. Product was purified from SiO 2 column and retention times of both enantiomers were monitored in HPLC Chiracel AD-H Column (ipropanol/hexane 1:9, 1 mL/min t 1 = 7.65 min and t 2 = 7.98 min). Then (R)-goniothalamin (1a) was synthesized by same procedure in the presence of R-BINOL starting from trans-cinnamaldehyde with 38% overall yield and 65% ee. Enantiomers were monitored in HPLC Chiracel AD-H Column under the same conditions and it was seen that the ratio of the peaks was different than that of racemic one and enantiomeric excess was calculated by using the area under these signals. Cytotoxic properties of synthesized compounds (1a and 4-10) were evaluated by MTT test on two cancer cell lines (PC-3 prostate cancer and MCF-7 human breast adenocarcinoma). Additional cytotoxicity tests for 1a, 4, and 11 were performed against two more cancer cell lines (DU-145, metastatic human prostate adenocarcinomas; LNCAP, lymph node metastasis of human prostate adenocarcinoma). As mentioned above, a Michael acceptor in lactone ring is crucial for cytotoxicity, similarly compounds 14a-g have also a Michael acceptor in their structures. Although they are not lactones they may also possesses anti-proliferative property. To better understand the importance of the lactone ring, compounds 14b-g were also tested against PC-3 and MCF-7 cell lines. IC 50 values of all MTT tests are listed in Table 2 .
It is found that, all of the lactone products have more potent cytotoxicity over tested cell lines compared to their acrylate precursors. Interestingly, in case of acrylates there could not be found any structure-activity relationship, while anti-proliferative effects of lactone derivatives imply a structure dependent activity. Compound 14e was the most active one among the tested acrylate derivatives.
It is observed that, analogues 4 and 5 have slightly better anti-proliferative properties compared to (R)-goniothalamin which may be the result of either restriction of rotation around the styrene part of the molecule or steric effect of additional atoms in the 2-naphthyl and 3-quinoyl substituent. On the other hand compound 11 is four and two times less cytotoxicity in PC-3 and MCF-7 cells respectively, compared to its enantiomer 4. This result was in agreement with those reported for (R)-and (S)-goniothalamin. 17 Sterically the most hindered analogue 10 has the weakest activity among the tested lactones. 1-Naphthyl substituted (R)-5,6-dihydro-2H-pyran-2-ones (6, 8, and 9) gave more promising results. Especially compound 9 is 80 times more potent compared to (R)-goniothalamin in PC-3 cells (IC 50 = 50 nM), and 40 times more potent compared to (R)-goniothalamin in MCF-7 cells (IC 50 = 440 nM). Structurally 1-naphthyl derivatives seem much closer to the goniothalamin analogue which has a cisdouble bond in its linker domain (2) . Contrarily it is discussed above that compound 2 has diminished cytotoxicity compared to 1a. 
Conclusion
The enantioselective syntheses of nine new 6-aryl substituted (R)-5,6-dihydro-2H-pyran-2-ones were accomplished. Cytotoxic activities of these compounds showed that, restriction of the rotation around the single bond between the phenyl ring and double bond somehow causes an enhancement in the cytotoxicity. In addition, size of the substituent and the stereochemistry in the lactone ring are also important, (R) enantiomer has lower IC 50 value for 2-naphthyl substituted analogues. 1-Naphthyl substitution in the lactone ring dramatically enhanced the activity. Any additional methyl substitution in the naphthalene ring at position 2 and 4 produce highly cytotoxic compounds. 
. General procedures
Reagents were commercial grade and were used as supplied. Dichloromethane was distilled over calcium hydride. Reactions were monitored by TLC using Merck TLC plates (Silicagel 60 F 254 ). Chromatographic separations were performed using 70-230 mesh silica gel. Solvents, required for SiO 2 column chromatography, were commercial grade and were used as supplied. Solvents, required for HPLC, were spectrometric grade and were used as supplied. 1 H NMR and 13 C NMR data were recorded on a Varian 400-MR (400 MHz) spectrometer. Chemical shifts for 1 H NMR and 13 C atmosphere. The resulting solution was allowed to warm up to room temperature for 1 h. and then 61 mg (0.26 mmol) of silver (I) oxide was added. The mixture was stirred for 5 h without any exposure to direct day light. After dilution with 4.5 mL of dichloromethane, 150 mg (0.524 mmol) of R-BINOL was added and stirred for 2 h. The resulting mixture was cooled down to À75°C, and then treated sequentially with 409 mg (2.62 mmol) of 2-naphthaldehyde and 953 mg (893 lL, 2.88 mmol) of allyltributyltin. The mixture was stirred for 16 h and allowed to warm up to room temperature. After the reaction was completed, the reaction mixture was filtered through a short pad of Celite, then quenched with saturated NaHCO 3 ; Enantiomeric excess was found as 80% with HPLC-Chiracel AD-H column (i-propanol/hexane 10:90, 1 mL/min t 1 = 5.51 min 'major enantiomer', t 2 = 5.97 min 'minor enantiomer').
(R)-(+)-1-(Quinolin-3-yl)-but-3-en-1-ol (13b)
After the removal of solvent under vacuum, purification of the crude by column chromatography on silica gel (ethyl acetate/hex-anes, 1:6) furnished 253 mg of (R)-(+)-1-(quinolin-3-yl)-but-3-en- 
After the removal of solvent under vacuum, purification of the crude by column chromatography on silica gel (ethyl acetate/hexanes, 1:8) furnished 214 mg of (R)-(+)-1-(naphthalen-1yl)-but-3-en- 
After the removal of solvent under vacuum, purification of the crude by column chromatography on silica gel (ethyl acetate/ hexanes, 1:8) furnished 104 mg of (R)-(+)-1-(2-methylnaphthalen-1-yl)-but-3-en-1-ol (13e) as a colorless oil with 19% yield. R f = 0.34 (ethyl acetate/hexanes, 1:6); ½a 21 D (could not be measured) (c 1.04, many different solvents were tried); 1 21, 21 .00; Enantiomeric excess was found as 96% with HPLC-Chiracel AD-H column was used and ee was found as 93%, (i-propanol/hexane 5:95, 1 mL/ min t 1 = 3.70 min 'minor enantiomer', t 2 = 4.50 min 'major enantiomer'). 4.1.9. (S)-(À)-1-(Naphthalen-2-yl)-but-3-en-1-ol (15) Catalyst was prepared by using S-BINOL instead of R-BINOL, and same procedure was applied for aldehyde 12a. After the removal of solvent under vacuum, purification of the crude by column chromatography on silica gel (ethyl acetate/hexanes, 1:8) furnished 133 mg of (S)-(À)-1-(naphthalen-2-yl)-but-3-en-1-ol (15) found: 198 (2%), 179 (100%), 166, 157, 129; Enantiomeric excess was found as 82% with HPLC-Chiracel AD-H column (i-propanol/ hexane 10:90, 1 mL/min t 1 = 5.51 min 'minor enantiomer', t 2 = 5.95 min 'major enantiomer').
(R)-(+)-1-(Naphthalen-2-yl)but-3-enyl acrylate (14a)
A solution of 302 mg (1.523 mmol) of 13a in 3.0 mL of dichloromethane was cooled down to 0°C; then 248 mg of acryloyl chloride (223 lL, 2.74 mmol) and 554.6 mg of triethyl amine (770 lL, 5.48 mmol) were sequentially added. The mixture was warmed to room temperature and stirred for 22 h under nitrogen atmosphere. The resulting mixture was filtered through a short pad of Celite, poured into water, and the product was extracted with 3Â 25 mL of dichloromethane. The combined organic layer was concentrated under reduced pressure and purification of this residue by column chromatography on silica gel (ethyl acetate/hexane, 1:8) gave 204.8 mg of (R)-1-(naphthalen-2-yl)but- 3 found: 252 (2%), 224, 178, 156 (100%), 128, 68; Enantiomeric excess was found as 79% with HPLC-Chiracel AD-H column (i-propanol/hexane 10:90, 1 mL/min t 1 = 2.80 min 'major enantiomer', t 2 = 3,50 min 'minor enantiomer'). 26 ; Enantiomeric excess was found as 92% with HPLC-Chiracel AD-H column (i-propanol/hexane 1:99, 1 mL/min t 1 = 19.50 min 'major enantiomer', t 2 = 21.50 min 'minor enantiomer').
(R)-(+)-1-(Naphthalen-1-yl)-but-3-enyl acrylate (14c)
Purification of the crude product by column chromatography on silica gel (ethyl acetate/hexane, 1:8) gave 186 mg of (R)-(+)-1-(naphthalen-1-yl)-but-3-enyl acrylate (14c) with 69% yield. R f = 0.63 (ethyl acetate/hexanes, 1:4); ½a 26 D +7.92 (c 2.12, EtOAc) was detected for 73% ee in the second synthesis); 1 21, 130.55, 129.15, 128.77, 128.73, 126.54, 125.89, 125.45, 124.11, 123.39, 118.23, 72.73, 40.60 ; Enantiomeric excess was found as 44% with HPLC-Chiracel AD-H column (i-propanol/hexane 5:95, 1 mL/min t 1 = 3.21 min 'major enantiomer', t 2 = 4.22 min 'minor enantiomer').
(R)-(À)-1-(Quinolin-4-yl)-but-3-enyl acrylate (14d)
Purification of the crude product by column chromatography on silica gel (ethyl acetate/hexane, 1:8) gave 43 mg of (R)-(+)-1-(quinolin-4-yl)-but-3-enyl acrylate (14d) as a yellow oil with 56% yield. 11, 20.92 ; Enantiomeric excess was found as 100% with HPLC-Chiracel AD-H column (i-propanol/hexane 1:99, 0.7 mL/min t 1 = 4.00 min single peak).
(R)-(+)-1-(4-Methylnaphthalen-1-yl)-but-3-enyl acrylate (14f)
Purification of the crude product by column chromatography on silica gel (ethyl acetate/hexane, 1:12) gave 50 mg of (R)-(+)-1-(4-methylnaphthalen-1-yl)-but-3-enyl acrylate (14f) as a light yellow oil with 56% yield. R f = 0.45 (ethyl acetate/hexanes, 1:8); (½a 31 D +13.33 (c 2.73, CH 2 Cl 2 ) was detected for 78% ee in the second synthesis); 1 13 13 
(S)-(À)-1-(Naphthalen-2-yl)-but-3-enyl acrylate (16)
Purification of the crude product by column chromatography on silica gel (ethyl acetate/hexane, 1:8) gave 124 mg of (S)-(À)-1-(naphthalen-2-yl)-but-3-enyl acrylate (16) To a stirred solution of 80.2 mg of Grubbs' catalyst (10 mol%) in 8 mL dichloromethane at 60°C was added a solution of 205 mg (0.812 mmol) of 14a in 90 mL of dichloromethane. The resulting mixture was heated for 14 h. At the end of this period, the mixture was cooled to room temperature and concentrated under reduced pressure. The crude was purified by column chromatography on silica gel (ethyl acetate/hexanes, 1:8) furnished 159 mg (R)-5,6dihydro-6-(naphthalen-2-yl)pyran-2-one (4) The crude product was purified by column chromatography on silica gel (ethyl acetate/hexanes, 1:8) furnished 125 mg of (R)-(+)-6-(naphthalen-1-yl)-5,6-dihydro-2H-pyran-2-one (6) The crude product was purified by column chromatography on silica gel (ethyl acetate/hexanes, 1:8) furnished 9 mg of (R)-(+)-6-(quinolin-4-yl)-5,6-dihydro-2H-pyran-2-one (7) as a light yellow solid with 34% yield. R f = 0.14 (ethyl acetate/hexanes, 1:1). (½a 26 D +313.91 (c 0.63, CH 2 Cl 2 ) was detected for 86% ee in the second synthesis). 1 21, 117.44, 68.85, 42.80, 29.67 ; Enantiomeric excess was found as 95% with HPLC-Chiracel AD-H column (i-propanol/ hexane 5:95, 1 mL/min t 1 = 6.42 min 'major enantiomer', t 2 = 7,15 min 'minor enantiomer'). The crude product was purified by column chromatography on silica gel (ethyl acetate/hexanes, 1:8) furnished 27 mg of (R)-(+)-6-(4-methylnaphthalen-1-yl)-5,6-dihydro-2H-pyran-2-one (9) The crude product was purified by column chromatography on silica gel (ethyl acetate/hexanes, 1:8) furnished 78 mg of (S)-(À)-6-(naphthalen-1-yl)-5,6-dihydro-2H-pyran-2-one (11) Four cell lines including PC-3, DU145, LNCaP, and MCF-7 were obtained from the ATCC (USA) culture collection. Cells were cultured in RPMI-1640 (Invitrogen, USA) or DMEM (Invitrogen, USA) supplemented with 5-10% fetal bovine serum (Sigma, USA), by additions of 100 IU/mL penicillin and l lg/mL streptomycin. Cells were grown in humidified atmosphere with 5% CO 2 at 37°C. Cytotoxic effects of compounds were analyzed by MTT assay which is based on the cellular reduction of the tetrazolium salt 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT, Sigma Chemicals) to a purple formazan product by mitochondrial dehydrogenases of viable cells. Cell proliferation was determined by adding 0.5 lg/mL per well, prepared as a sterile stock-solution of 5 mg/mL in Dulbeccos-phosphate-buffered saline (Gibco), diluted 1:10 in medium prior to use. Medium was removed 4 h later and blue formazan crystals solubilized in 200 lL 100% dimethylsulfoxate (DMSO) per well. Amounts of blue formazan product were quantified at 570-690 nm using a microplate reader (Versamax, Tunable Microplate Reader, USA). For all cell lines, strong correlations between numbers of cells present and amounts of MTT formazan product were observed. Each cell type was incubated with various doses of 1a, 4, and 11 for 72 h at 37°C and subjected to MTT assays to measure IC 50 values. The data were obtained from three independent assays using two wells for each assay. Cell viability was calculated as% cell viability.
MTT Test for compounds 5-10 and 14b-14g
Human Prostat Cancer (PC-3) cell line was kindly provided by Assoc. Prof. Kemal S. Korkmaz (Ege University, Engineering Faculty, Department of Bioengineering), human breast cancer (MCF-7) cell line was obtained from Oguz Bayraktar. PC-3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 5% fetal bovine serum (FBS), 1 lg/mL streptomycin/100 IU/mL penicillin, MCF-7 cell line was maintained in Roswell Park Memorial Institute-1640 (RPMI-1640) containing 15% FBS (BIO-IND), 1 lg/ mL streptomycin/100 IU/mL penicillin incubated at 37°C in the dark with 5% CO 2 humidified incubator and passaged when they reached 80-85% confluency. Cells used in experiments were maintained from 10th to 20th passages.
To investigate the cytotoxic activity of the compounds, 95 ll of cell suspension was inoculated into 96-well microculture plates at 1Â 10 4 cells density per well in culture media containing FBS, penicillin/streptomycin. Compounds were dissolved in dimethyl sulfoxide (DMSO) (Sigma, USA), filter sterilized, diluted at the appropriate concentrations with the culture medium. In all wells, 1% DMSO concentration was fixed. Dilutions of compounds were freshly prepared before each experiment. After 24 h cultivation for cell attachment, extracts were added at final concentrations 50, 25, 1, 0.5, 0.1, 0.05, and 0.01 lM for triplicate assay. Cells were treated with the extracts for 48 h and cytotoxic effects were determined by tetrazolium (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma, USA) based colorimetric assay. This method depends on the cleavage of tetrazolium salt to purple formazan crystals by mitochondrial enzymes of metabolically active cells. 29 Briefly, 4 h before the end of incubation period, medium of the cells was removed and wells were washed by pre-warmed phosphate-buffered saline (PBS) to remove any trace of compounds and to prevent color interference while optical density determina-tion. MTT stock-solution (5 mg/mL) was diluted at 1:10 ratio into complete culture media, 100 ll of MTT dilution was added into each well and incubated at 37°C in humidified atmosphere. After 3.5 h plates were centrifuged at 1800 rpm for 10 min at room temperature to avoid accidental removal of formazan crystals. Crystals were dissolved with 100 ll DMSO. The absorbance was determined at 540 nm. Results were represented as percentage cell viability.
